It’s that time again — last week’s Top Ten posts!!!

Back in February, we wrote a piece on Patrick Swayze and asked whether the Novartis (NVS) drug vatalanib worked on the actor’s pancreatic cancer. The post is like the Titanic of posts – it consistently receives the biggest audience of readers every single week. There’s been a few days where it came in second or third, but it never falls below that. And so, this week, CTIC and the Pixantrone obsession has failed to defend their title. We also have Follica back in the Top Ten and a high interest in Facet Biotech’s daclizumab.

OK, here we go — last week’s Top Ten/most read posts –the posts that made us all cry, laugh, gasp and have all sorts of crazy feelings:

10 – Venture Update: Follica Gets a CEO (Plus, Dear Daphne)

9 – Facet Biotech: Daclizumab for Multiple Sclerosis, Hype or Truth?

8 – More Pfizer: 40,000 Layoffs Not Cheap, Wyeth Gets Short Stick, Stock Price Seeing Lifeline?

7 – Solvay Throwing Curve Balls on Rumors, J.P.Morgan Thinks Takeda?

6 – ASCO Watch 09: Genta, Exelixis, Roche/Genentech, Cell Therapeutics

5 – The 1Q Graveyard Roundup: CTIC Escapes, La Jolla’s Last Shot, Somaxon Death Inevitable

4 – Cell Therapeutics Shareholders to Adam Feuerstein: You’re a D@$*!!!

3 – Cell Therapeutics – Pressure Building, ASCO Coming Soon, The Bear View

2 – More Cell Therapeutics: OPAXIO vs. Pixantrone, The Race is On

And of course, the most read post from last week is…

1 – Did Vatalanib Work for Patrick Swayze?

And that’s that…

Related Posts